The diagnostic performance of 18F-PSMA-1007 PET/CT in the detecting biochemical recurrence (BCR) of prostate cancer was evaluated in 8 studies (Zhou et al., 2022; Mingels et al., 2022; Watabe et al., 2021; Ahmadi Bidakhvidi et al., 2021; Giesel et al., 2018; Giesel et al., 2019; Poterszman et al., 2024; Sprute et al., 2021). This evidence concerns the gene FOLH1 and prostate cancer.